Guidance
← Отчётные звонки
01
02
03
04 05 06
Тон
Капзатраты
A1 A2 A3 A4
CTVA
FY2026 Q2
Улучшается
Отчётный звонок Corteva, Inc.
Вывод Buzzberg
Full-year guidance raised with EBITDA and EPS increases.
Corteva beat expectations in Q2 and raised full-year 2026 guidance on strong execution in seed and crop protection. The company is on track to complete its separation on October 1st, with management outlining a clear path to meeting long-term targets. Key drivers are technology adoption, licensing growth, and cost/productivity improvements, offset by competitive pricing pockets in Brazil. Raised 2026 guidance: EBITDA to $4.1-4.3B, EPS to $3.60-3.80, margin to 22.5-23.5%.
Вывод Buzzberg Full-year guidance raised with EBITDA and EPS increases. Corteva beat expectations in Q2 and raised full-year 2026 guidance on strong execution in seed and crop protection. The company is on track to complete its separation on October 1st, with management outlining a clear path to meeting long-term targets. Key drivers are technology adoption, licensing growth, and cost/productivity improvements, offset by competitive pricing pockets in Brazil. Raised 2026 guidance: EBITDA to $4.1-4.3B, EPS to $3.60-3.80, margin to 22.5-23.5%. Читать полный анализСвернуть анализ
Corteva beat expectations in Q2 and raised full-year 2026 guidance on strong execution in seed and crop protection. The company is on track to complete its separation on October 1st, with management outlining a clear path to meeting long-term targets. Key drivers are technology adoption, licensing growth, and cost/productivity improvements, offset by competitive pricing pockets in Brazil. Raised 2026 guidance: EBITDA to $4.1-4.3B, EPS to $3.60-3.80, margin to 22.5-23.5%.
- H1 2026: Sales up 4% to $11.3B, EBITDA up 10% to $3.7B, margin up 190bps to 32.8%.
- Separation (Vylor) on track for Oct 1, with net synergies impact largely offset to a ~$25M headwind for 2026.
- Crop protection new product portfolio on track to reach $2B revenue this year, offsetting price declines in generics.
Выручка$6.379B+30% к/к
EPS$2.30+53% к/к
Валовая маржа54.35%Факт
Операционная маржа30.02%Факт
6 подтверждённых тезисов
Что важно сейчас
Самые значимые изменения по итогам звонка.
Separation
Separation on track for October 1 with minimal dis-synergies.
Crop Protection
Crop protection new products approaching $2 billion revenue.
Показать ещё 3 тезиса
Seed
Seed licensing business three years ahead of plan.
Pricing
Brazil crop protection pricing remains under pressure.
Demand
Brazilian farmer credit tightness noted as a watch item.
Отчётный период
Фактические результаты
| Показатель | Факт | Изменение |
|---|---|---|
| Выручка | $6.379B | +30% к/к |
| EPS | $2.30 | +53% к/к |
| Валовая маржа | 54.35% | Факт |
| Операционная маржа | 30.02% | Факт |
| Свободный денежный поток | $-3.56B | -20% к/к |
| Капзатраты | $0.203B | Факт |
Прогнозные данные
Прогноз компании
| Показатель | Период | Диапазон | Середина | Статус |
|---|---|---|---|---|
| EPS | FY2026 | $3.60–$3.80 | $3.70 | Повышен |
| Операционная маржа | FY2026 | 22.5%–23.5%В соответствии с консенсусом | 23% | Повышен |
| Операционная маржа | FY2026 | $4.1B–$4.3B | $4.2B | Повышен |
AI, капзатраты и спрос
Оценка менеджмента
Confident
Management expressed confidence in raising full-year guidance, highlighted strong execution, and emphasized on-track separation progress, all conveying a positive outlook.
Инвестиции и мощности
Management discussed productivity improvements, cost management, and asset optimization, but no specific forward-looking capex figures were provided.
Внешние сигналы
Альфа цепочки поставок · 4с момента звонка
Corteva's licensing business is running three years ahead of plan, contributing to the 'net royalty positive' position for the first time.
Доказательства
“licensing is literally three years ahead of our original plan, which is pretty astonishing considering that is a brand new business for us.”
Corteva anticipates a Q3 operating EBITDA loss of ~$100M, more typical of past years, with H2 EBITDA expected to be flat at ~$500M.
Доказательства
“if you recall, our second half in 2025 was up 16% versus 2024. So we are comparing against a pretty strong half at about $500 million. ... Our second half is about 12% of our full year guide. And that's very much in line with the past four…”
Management states that the China-to-Brazil export market is stable, and the channel is not oversupplied, ready for the next season. This suggests the prior high-import inventory deluge is over.
Доказательства
“when you look at Chinese exports into Brazil, they're essentially stable. They're not going down, but they're certainly not going up.”
Corteva is seeing competitive tension and price declines on off-patent molecules (e.g., pre-emergent herbicides in Brazil), but it has pre-emptively lowered its cost base on these products, allowing it to maintain margins and share.
Доказательства
“We were really anticipating that we were going to see generic pressure. And we went really to work on our cost structure. And what we found is that we had to, of course, lower our prices because there's generics in the marketplace. But if…”
Методология и полнота
Анализ основан только на заявлениях менеджмента. Показаны все подтверждённые упоминания компаний: 0. Фактические результаты и прогнозы разделены. Публичные доказательства ограничены восемью короткими атрибутированными цитатами. AI-анализ может быть неполным или ошибочным — проверяйте важные утверждения по первоисточнику.